亚太区股市随美股全面造好 台股续涨3.4%屡创逾30年高 港韩股升1.4%-1.9%
美股昨晚扭两连跌全面反覆回升0.4%-1.7%,美国疫情持续反弹,但Moderna研发新冠肺炎疫苗开始进入最後阶段大规模临床测试,若测试成功,料年底可广泛使用,股价急涨9%,加上美国6月核心耐用品订单及达拉斯联储制造业指数升幅均胜预期,市场也憧憬美国政府将会推出新一轮刺激经济措施,过半蓝筹造好,微软、思科、卡特彼勒、3M、苹果、默克及陶氏升逾1-3%,但Travelers、摩通、雷神、波音及上周五已急跌英特尔跌1.4%-2%,拖累道指仅反覆回升0.4%收26,584;费城半导体指数急弹3.2%,fb、亚马逊及Alphabe也升逾1%,带动标普及纳指弹0.7%及1.7%。不过,欧洲疫情反弹,欧洲主要股市除7月Ifo商业景气指数升至五个月高的DAX逆稳外,全部续受压,尤其是疫情急弹西班牙续挫1.7%。
美股期货全面续弹0.4%-0.5%。亚太区股市早段全部向好,尤其是韩股续升1.9%报2,259;台湾加权指数延续昨天回升2.3%破顶强势,今早再急升3.4%报13,021,屡创30年半高;澳洲200续弹1%报6,106;新加坡及新西兰股价回升0.5%及0.7%,分别报2,589及11,669;马股微弹0.2%报1,594。
美汇指数跌破94曾低见93.476创逾两年低,美元兑日圆连跌第三天,报105.12屡创逾四个月低,日经扭两连跌,回升0.5%,报22,832。沪指及深成继昨天反覆微弹後,今天高开近0.7%及1%,分别报3,226及13,107。
本港昨天新增145宗新型肺炎确诊再创单日新高,其中142宗属本地感染。此外,本港6月出口额同比意外续降1.3%,市场原预期弹4.2%,进口额年降明显收窄至7.1%,优於市场预期弹5.5%。期内,贸易逆差333亿元,超出市场预期贸赤302亿元。港股继昨天反弹受制二万五关倒跌逾百点後,今早扭两连跌,在三大保险股、港交所(00388.HK)及重磅股腾讯(00700.HK)高开逾1%-2.8%带动,高开339点或1.4%报24,942。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.